Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor.
10.3779/j.issn.1009-3419.2019.01.07
- Author:
Zheng WANG
1
;
Shizhao CHENG
1
;
Fang ZHOU
1
;
Xingpeng HAN
1
;
Xike LU
1
;
Daqiang SUN
1
;
Xun ZHANG
1
Author Information
1. Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300000, China.
- Publication Type:Journal Article
- Keywords:
Lung;
Neuroendocrine tumor;
Therapy
- MeSH:
Disease-Free Survival;
Drug Therapy;
methods;
Humans;
Lung;
drug effects;
radiation effects;
surgery;
Lung Neoplasms;
pathology;
surgery;
therapy;
Neoplasm Grading;
Neuroendocrine Tumors;
pathology;
surgery;
therapy;
Outcome Assessment (Health Care);
Radiotherapy;
methods
- From:
Chinese Journal of Lung Cancer
2019;22(1):34-39
- CountryChina
- Language:Chinese
-
Abstract:
The lung is the second most common site of neuroendocrine tumors (NETs). Typical and atypical carcinoids are low-grade NETs of the lung. These rare tumors have received little attention and education is needed for treating physicians. The article describes the classifcation of lung NETs, the epidemiology and pathological characteristics. When lung NETs are diagnosed at an early stage, surgical intervention is often curative. For advanced lung NETs patients, different treatment methods including chemotherapy, somatostatin analogs, m-TOR inhibition, peptide receptor radioligand therapy, and biologic systemic therapy are discussed. The conclusions are generally extrapolated from the outcome of extra-pulmonary carcinoids. Prospective randomized well-designed trials are urgently needed to inform current recommendations on systemic treatment.
.
